Recruiting

Evaluation of Two Prednisolone Treatment Strategies for Newly Diagnosed, Untreated Rheumatoid Arthritis Patients

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of rheumatoid arthritis, a condition that causes pain and swelling in the joints. The study will use a medication called Prednisolone, which is a type of steroid that helps reduce inflammation and pain. Two different doses of Prednisolone will be used: 5 mg and 2.5 mg tablets, both taken orally. The purpose of the study is to evaluate two strategies for reducing the dosage of Prednisolone in patients who have recently been diagnosed with rheumatoid arthritis and have not been treated before.

Participants in the study will be randomly assigned to one of two groups. One group will follow a faster reduction of the low-dose Prednisolone, while the other group will follow a slower reduction of the same starting dose. The study will last for a period of up to 51 weeks, during which the effects of the treatment will be monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the effectiveness of the treatment strategies.

The study aims to determine if the faster reduction of Prednisolone is not worse than the slower reduction in managing the symptoms of rheumatoid arthritis. Throughout the study, the health and progress of the participants will be closely observed to ensure their safety and to gather information on the effectiveness of the treatment. The results will help in understanding the best approach to using Prednisolone for newly diagnosed patients with rheumatoid arthritis.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, you will be asked to provide a signed consent form. This confirms your agreement to participate and that you understand the study's purpose and procedures.
Step 2
Initial assessment
An initial assessment will be conducted to confirm your diagnosis of rheumatoid arthritis according to the 2010 classification criteria. This assessment ensures that you meet the study's inclusion criteria.
Step 3
Medication administration
You will be randomly assigned to one of two treatment strategies involving the medication prednisolone. This medication is taken orally in the form of tablets.
The dosage and frequency of prednisolone will depend on the specific treatment strategy you are assigned to. The study aims to compare a rapid reduction in dosage with a slower reduction, both starting from the same initial dose.
Step 4
Regular follow-up visits
You will attend regular follow-up visits to monitor your progress. These visits will include assessments of your clinical effectiveness, which is measured by the time-averaged DAS28 score at month 12.
Additional assessments will be conducted at months 6, 12, and 24 to evaluate improvements in pain, function, quality of life, fatigue, and general health.
Step 5
Safety monitoring
Throughout the study, your safety will be closely monitored. This includes tracking any adverse events (AEs) or serious adverse events (SAEs) that may occur during the 2-year duration of the study.
Step 6
Treatment evaluation
At months 12 and 24, the need for any additional treatment, such as the addition of a biological disease-modifying antirheumatic drug (bDMARD), will be evaluated based on the effectiveness of the initial treatment strategy.
Step 7
Study completion
The study is expected to conclude by December 31, 2025. Upon completion, the results will be analyzed to determine the effectiveness of the two treatment strategies.

Who can join the trial?

5 criteria

Signed consent form: You must agree to participate in the study by signing a consent form.
Diagnosis of Rheumatoid Arthritis (RA): You must have been diagnosed with rheumatoid arthritis according to the 2010 classification criteria.
Age 18 years or older: You must be at least 18 years old to participate.
Treatment-naive RA patients: You should not have received any prior treatment for rheumatoid arthritis.
Eligible for prednisolone treatment: You must be suitable for treatment with prednisolone, a type of medication, according to treatment guidelines, and have no reasons that would prevent you from taking this medication in the doses used for this study.

Who cannot join the trial?

10 criteria

Patients with any other serious health conditions that could interfere with the study.
Patients who are pregnant or breastfeeding.
Patients who have had a recent infection or illness that could affect the study results.
Patients who are currently participating in another clinical trial.
Patients who have a history of allergic reactions to the study medication.
Patients who are unable to follow the study procedures or instructions.
Patients with a history of drug or alcohol abuse.
Patients who have been diagnosed with a mental health condition that could interfere with the study.
Patients who have had a recent surgery or are planning to have surgery during the study period.
Patients who are taking medications that could interfere with the study medication.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Karolinska University Hospital
Verified
Solna, Sweden

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Prednisolone is a type of medication known as a corticosteroid, which is often used to reduce inflammation in the body. In this clinical trial, Prednisolone is being tested to see how effective it is in treating newly diagnosed rheumatoid arthritis. The study is comparing two different strategies for reducing the dose of Prednisolone over time. The goal is to find out if a faster reduction in the dose is just as effective as a slower reduction for patients with this condition. Prednisolone helps to manage symptoms like pain and swelling by calming down the immune system's response. This can help improve the quality of life for people with rheumatoid arthritis by making it easier for them to move and perform daily activities.

Prednisolone

What is already known about the treatment

Prednisolone – Prednisolone is a medication administered orally in the form of tablets. It is currently being studied in clinical trials for its effectiveness in treating newly diagnosed, untreated rheumatoid arthritis. The main therapeutic use of Prednisolone is to reduce inflammation and suppress the immune system in conditions like rheumatoid arthritis. At the molecular level, it works by mimicking the effects of cortisol, a natural hormone, to decrease inflammation and immune response. Prednisolone is classified as a corticosteroid, a type of steroid hormone used to treat various inflammatory and autoimmune conditions.

Investigated diseases

Rheumatoid arthritis – Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects the joints. It typically begins with inflammation in the synovial membrane, leading to swelling, pain, and stiffness, especially in the morning or after periods of inactivity. Over time, the inflammation can cause damage to the cartilage and bone within the joint, resulting in joint deformity and loss of function. The disease often progresses symmetrically, meaning it affects the same joints on both sides of the body. In addition to joint issues, rheumatoid arthritis can also affect other systems in the body, causing symptoms such as fatigue and general malaise. The progression of the disease can vary greatly among individuals, with periods of increased activity (flares) and periods of remission.